(7R,13R,17R)-17-[2-[4-(diethylaminomethyl)-2-methoxyphenoxy]ethyl]-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (7R,13R,17R)-17-[2-[4-(diethylaminomethyl)-2-methoxyphenoxy]ethyl]-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol
• 化学式: C₃₃H₄₇NO₃
• 分子量: 505.7
• InChiKey: OHCPNHFLPCVWRG-YQOGLFJVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• THERAPEUTIC AGENT FOR HYPERTENSION
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP1921085A1

  公开（公告）日：2008-05-14

  The present invention provides a novel hypertension therapeutic agent. The hypertension therapeutic agent of the present invention contains, as an active ingredient, a compound represented by formula (1): [F1] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型高血压治疗剂。 本发明的高血压治疗剂含有一种由式（1）代表的化合物作为活性成分： [F1] 或其药学上可接受的盐。
• NORPREGNANE DERIVATIVES FOR THE RISK REDUCTION OF BREAST CANCER
  申请人：Helix Twelve Pharmaceuticals Corporation, Inc.

  公开号：US20170157143A1

  公开（公告）日：2017-06-08

  In one embodiment, the application discloses a method for the prophylaxis or the treatment of a pre-cancerous lesion, including atypical intraductal breast hyperplasia, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising compound of the formula I.
• US9650408B2
  申请人：——

  公开号：US9650408B2

  公开（公告）日：2017-05-16